A laboratory testing kit that estimates the risk of breast cancer relapse in spite of anti-hormone treatment has received approval from the U.S. Food and Drug Administration (FDA). This technology is based on a gene signature known as “PAM50”.

Source: Discovery goes from the lab to the patient


David Cottle

UBB Owner & Administrator